)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
ESSA Pharma
ESSA Pharma (EPIX) investor relations material
ESSA Pharma has been acquired
ESSA Pharma AGM 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.AGM 2025 summary3 Oct, 2025
Opening remarks and agenda
Meeting held virtually, allowing security holders to participate, submit questions, and vote electronically via Computershare platform.
Rules for orderly conduct and voting procedures were outlined at the start.
David Parkinson chaired the meeting, with David Wood as Secretary and Dave Baines as scrutineer.
Corporate governance
Notice of meeting was sent in accordance with legal requirements, and quorum was confirmed as present.
Meeting was declared properly constituted for business transactions.
Shareholder proposals
Security holders considered and voted on a special resolution for a plan of arrangement involving multiple entities under a Business Combination Agreement.
Shareholders also considered a non-binding advisory resolution on executive compensation related to the arrangement.
Voluntary liquidation and dissolution of the company was proposed if the arrangement was not approved.
Appointment of PricewaterhouseCoopers LLP or another qualified liquidator was proposed in the event of liquidation.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ESSA Pharma
- Shareholders to vote on cash acquisition, CVRs, and potential liquidation; board recommends approval.EPIX
Proxy Filing - Shareholders are urged to approve a cash acquisition and CVR deal, with liquidation as the alternative.EPIXProxy Filing
- Annual meeting to vote on board size, director elections, pay, and auditor, with strong governance focus.EPIXProxy Filing
- Shareholders to receive cash and CVRs in XenoTherapeutics acquisition, unanimously board-approved.EPIXProxy Filing
- Shareholders to vote on acquisition, capital reduction, and cash distribution before winding up.EPIXProxy Filing
- Shareholders to receive cash and CVRs in acquisition; board unanimously supports approval.EPIXProxy Filing
- $80M capital return and winding-up transaction with Xeno; due bill trading set for August 19–25, 2025.EPIXProxy Filing
- US $80 million distribution and XenoTherapeutics acquisition set for shareholder approval.EPIXProxy Filing
- Masofaniten shows strong early efficacy in prostate cancer trials, with key phase II data due next year.EPIX2024 Cantor Fitzgerald Global Healthcare Conference
- Phase 1 combo data show 81% PSA90; phase 2 readout expected mid-2025.EPIXJefferies 2024 Global Healthcare Conference
ESSA Pharma
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
ESSA Pharma Inc. is a clinical-stage pharmaceutical company primarily focused on the development of novel therapies for the treatment of prostate cancer. The company is pioneering the creation of a new class of drugs known as "anitens," which are designed to disrupt the androgen receptor signaling pathway, a key driver in the progression of prostate cancer. ESSA's lead clinical candidate, masofaniten (formerly known as EPI-7386), targets the N-terminal domain of the androgen receptor, aiming to offer a novel approach for patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, especially those who have developed resistance to current anti-androgen therapies. The company is headquartered in Vancouver, Canada, and its shares are listed on the Nasdaq.